Please assess the completion status of the following clinical trial:

Trial Title: A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed Type 2 Diabetes Mellitus (T2DM) for at least 3 months prior screening~* On a stable treatment regimen for at least 2 months prior screening~* Medically stable on the basis of physical examination, medical history, and clinical laboratory tests performed at screening and 2 days before administration of the study medication~* Fasting plasma glucose (FPG) concentrations between 140 mg/dL and 270 mg/dL on 2 days before administration of the study medication~* Agrees to protocol-defined use of effective contraception~Exclusion Criteria:~* History of other types of diabetes and complications or secondary forms of diabetes~* History of eating disorder or recent significant changes in body weight (ie, more or equal to 5 percent over 3 months prior to screening) due to dieting or nutritional treatments~* Taking antihyperglycemic agents (insulin, exenatide, and liraglutide) within 6 months or thiazolidinedione within 3 months of 2 days before administration of the study medication~* Clinically significant abnormal electrocardiogram~* History of, or currently active, significant illness or medical disorders, retinal disease, tuberculosis~* Clinically important serious infection, positive for serology at screening (hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus antibodies)

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-41443532 250 mg (Type: EXPERIMENTAL): Participants will receive JNJ-41443532 250 mg in morning and evening for 28 days.
- JNJ-41443532 1000 mg (Type: EXPERIMENTAL): Participants will receive JNJ-41443532 1000 mg (4 X 250 mg) in morning and evening for 28 days.
- Pioglitazone (Type: ACTIVE_COMPARATOR): Participants will receive pioglitazone 30 mg in morning for 28 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive matching placebo for JNJ-41443532 and pioglitazone for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).